Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Novartis AGNYSE: NVS

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 7.4% from a year ago

Net receivables stood at $9.85B at the end of Q2 FY2026, up 7.4% from a year earlier and up 2.6% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Net receivables amounted to 8.1% of total assets at the end of Q2 FY2026, down 0.7 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +7.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$9.85B+2.6% QoQ
Last fiscal yearDec 2025
$10.93B+33.2% YoY
Year agoJun 2025
$9.18B+7.4% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.4%——
1 year+33.2%——
3-year CAGR+3.4%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
10.93B USD
Year-over-year change
+33.2%
4-year CAGR
+3.2%

Net Receivables vs competitors

How NVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.4% is the 6th highest of 11, against a peer median of +6.9%.
  • Net receivables amounts to 8.1% of total assets for NVS, versus a peer median of 10.2%.
NVS Competitors
Net Receivables for NVS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NVONovo Nordisk A/SJun 2026DKK 108.51B DKK+26.4%+9.6%18.2%
JNJJohnson & JohnsonSep 2026$18.99B USD+7.8%+0.5%9.6%
AZNAstraZeneca PLCSep 2026$16.35B USD+14.0%+18.2%13.7%
ABBVAbbVie Inc.Jun 2026$13.82B USD+9.4%+3.8%10.2%
MRKMerck & Co., Inc.Jun 2026$12.56B USD+6.1%+10.3%9.7%
PFEPfizer Inc.Jun 2026$12.49B USD-22.4%+2.9%6.2%
BMYBristol-Myers Squibb CompanyJun 2026$10.55B USD-30.1%+1.4%12.0%
NVSNovartis AGJun 2026$9.85B USD+7.4%+3.4%8.1%
SNYSanofiJun 2026€9.21B EUR+12.2%+0.9%7.1%
GSKGSK plcJun 2026£8.03B GBP-23.9%+7.6%13.1%
GILDGilead Sciences, Inc.Jun 2026$5.06B USD+5.7%+0.9%10.2%
Peer median (excluding NVS) —+6.9%+3.4%10.2%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents12.41B7.52B13.39B11.46B11.44B
Short-term Investments15.71B11.1B569M1.89B155M
Net Receivables9.62B9.89B9.38B8.21B10.93B
Inventory6.67B7.18B5.91B5.72B6.27B
Other Current Assets216M315M466M1.43B514M
Total Current Assets45.72B36.91B30.48B29.7B30.46B
Property, Plant & Equipment (Net)13.11B12.2B10.92B10.87B12.35B
Goodwill29.6B29.3B23.34B24.76B25.57B
Intangible Assets34.18B31.64B26.88B26.92B29.41B
Long-term Investments2.27B1.61B1.83B1.13B2.3B
Tax Assets3.74B3.74B4.31B4.36B10.06B
Other Non-current Assets3.18B2.06B2.18B4.51B5.42B
Total Non-current Assets86.08B80.54B69.46B72.54B85.11B
Total Assets131.8B117.45B99.95B102.25B115.57B
Account Payables5.55B5.15B4.93B4.57B4.46B
Short-term Debt6.23B5.88B6.08B8.09B5.78B
Tax Payables3.03B3.37B2.41B2.23B2.58B
Deferred Revenue123M123M98M127M0
Other Current Liabilities12.44B11.21B9.84B10.38B12.82B
Total Current Liabilities30.21B28.66B26.39B28.69B27.28B
Long-term Debt22.9B20.24B18.44B21.37B29.59B
Deferred Tax Liabilities3.07B2.69B2.25B2.42B8.02B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.17B4.91B4.52B4.08B2.48B
Total Non-current Liabilities33.77B29.37B26.81B29.43B41.74B
Total Liabilities63.97B58.03B53.2B58.12B69.02B
Common Stock901M890M825M793M766M
Retained Earnings70.99B63.54B49.65B46.56B44.72B
Accumulated OCI(4.19B)(5B)(3.77B)(3.26B)694M
Other Stockholders Equity00000
Minority Interest167M81M83M80M419M
Total Equity67.82B59.42B46.75B44.13B46.55B
Total Debt31.03B27.91B26.35B31.26B37.03B
Net Debt18.62B20.39B12.96B19.8B25.6B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.